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Abstract
The newly recognized sensory role of bladder urothelium has generated intense 
interest in identifying its novel sensory molecules. Sensory receptor TRPV4 may 
serve such function. However, specific and physiologically relevant tissue actions 
of TRPV4, stretch-independent responses, and underlying mechanisms are unknown 
and its role in human conditions has not been examined. Here we showed TRPV4 
expression in guinea-pig urothelium, suburothelium, and bladder smooth muscle, 
with urothelial predominance. Selective TRPV4 activation without stretch evoked 
significant ATP release—key urothelial sensory process, from live mucosa tissue, 
full-thickness bladder but not smooth muscle, and sustained muscle contractions. 
ATP release was mediated by Ca2+-dependent, pannexin/connexin-conductive path-
way involving protein tyrosine kinase, but independent from vesicular transport and 
chloride channels. TRPV4 activation generated greater Ca2+ rise than purinergic ac-
tivation in urothelial cells. There was intrinsic TRPV4 activity without exogeneous 
stimulus, causing ATP release. TRPV4 contributed to 50% stretch-induced ATP re-
lease. TRPV4 activation also triggered superoxide release. TRPV4 expression was 
increased with aging. Human bladder mucosa presented similarities to guinea pigs. 
Overactive bladders exhibited greater TRPV4-induced ATP release with age depend-
ence. These data provide the first evidence in humans for the key functional role of 
TRPV4 in urothelium with specific mechanisms and identify TRPV4 up-regulation 
in aging and overactive bladders.
K E Y W O R D S
aging, ATP release, overactive bladders, TRPV4 receptor, urothelium
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1 |  INTRODUCTION
Age-related diseases present a huge societal challenge to our 
aging society. One class of highly prevalent, costly but un-
der-studied debilitating chronic aging consequences is blad-
der disorders such as overactive bladder and recurrent bladder 
infections. Bladder diseases have a prevalence of 15%-20% 
rising to 40% over the age of 65 years, seriously reduce the 
quality of life and are the main reasons for entering into care-
homes. Specific treatment is currently not available due to 
poor understanding of their pathogenesis.
The urothelium, the inner epithelial lining of the urinary 
bladder, has recently been recognized as a new sensory struc-
ture in addition to its classic barrier function.1 Release of ATP 
from the urothelium in response to the physiological stimulus of 
bladder distension,2 expression of purinergic receptors (P2X3) 
on sensory nerve ending beneath the urothelium,3 and the abil-
ity of ATP to trigger afferent firing4,5 provide experimental ev-
idence for this tissue layer to function as a sensory tissue, with 
ATP as the sensory mediator. P2X3 deletion-induced suppres-
sion of the micturition reflex and afferent firing3,5 gives further 
weight to its physiological relevance. Expression of vanilloid 
receptors on the urothelium6 and the effect of TRPV1 deletion 
on bladder voiding7 suggest that this tissue can respond to nox-
ious stimuli such as high temperature and acidic pH. Changes 
to the urothelium in pathological animal models8-11 and human 
bladder pathologies12-14 emphasize a role of this structure in 
pathogenesis of bladder dysfunction.
A sensory role of the urothelium is further evidenced 
by expression of a variety of receptors typically expressed 
in sensory neurones, and nociceptive and mechanorecep-
tive cells.9,15-23 These “sensory molecules” may potentially 
enable the urothelium to respond to a range of physiologi-
cal and pathological stimuli.1 Experimental proof of these 
molecules functioning as sensory molecules will greatly 
enhance our understanding of urothelial sensory function. 
Some purinoreceptors and muscarinic receptors on the 
urothelium have been shown to function as sensory recep-
tors for physiological signals.24 Most of the other receptors, 
however in particular, those receptors that sense patho-
logical stimuli, have not yet been adequately explored. 
Identification of a pathological sensory molecule will be a 
major step forward in understanding the pathological role 
of the urothelium.
One such potential sensory molecule is the transient recep-
tor potential vanilloid 4 (TRPV4) channel, a TRP superfamily 
non-selective cation channel preferentially permeable to Ca2+, a 
major second messenger.25,26 TRPV4 is commonly considered 
to be mechano- or osmo-sensor27-30 and can also be activated by 
moderate heat.26,31 This indicates significant constitutive activ-
ity at physiological temperatures and an up-regulation in fever 
and local temperature rise. Certain chemical stimuli are also 
able to activate TRPV4.25,32-34 As many of the above factors 
are encountered during inflammatory conditions, TRPV4 will 
respond to inflammation and hence acts as pathological sensor.
TRPV4 expression has been demonstrated by immunostain-
ing in urothelium from mouse35,36 and rat.35 TRPV4-positive 
staining was also reported in human urothelial umbrella cells, 
albeit from limited samples.37 However, the tissue distribution 
of TRPV4 in the bladder wall, their molecular identification 
and quantification remain to be determined.
The function of TRPV4 was first shown in cultured urothe-
lial cells as a Ca2+ rise in response to 4α-phorbol 12,13-dide-
canoate (4α-PDD), an early non-specific TRPV4 agonist,20,35,38 
not selective for TRPV4.39 4α-PDD also increased ATP release 
from these cultured urothelial cells.38,40 Hypotonic cell swell-
ing/stretch-induced Ca2+ rise and ATP release from the cul-
tured urothelial cells has been suggested to be due to TRPV4 
activity in these studies. These previous studies focused mainly 
on cultured urothelial cells which are subject to phenotypic 
changes,41 and stretch as a method of investigating TRPV4, 
which activates many stretch-sensitive but TRPV4-independent 
processes, and have not used selective TRPV4 activator and 
antagonist.39,42,43 Gevaert et al35 further reported that TRPV4-
deficient mice exhibited a decreased spontaneous activity in 
isolated bladder strips, and decreased stretch-induced ATP re-
lease in isolated whole bladders, although measurement of ATP 
release directly from the urothelium layer was not performed. A 
major step forward in TRPV4 physiology awaits clarification of 
the mode of action for TRPV4 in native urothelium and smooth 
muscle, preferably in multicellular preparations to preserve the 
functional syncytium10 and in response to stretch and stretch-in-
dependent stimuli which has been little studied. More impor-
tantly, the functional role of TRPV4 in human conditions has 
not been explored, prompting urgent need for this translational 
investigation.
The objectives of this study are first to characterize the 
properties of TRPV4 and its contribution to urothelial and 
smooth muscle activation, through specific activation of the 
receptor in native animal bladder tissue, and the underlying 
subcellular mechanism and, second, to demonstrate its rele-
vance to human conditions and finally to investigate changes 
to this receptor in aging and pathology. The data from this 
study provide crucial evidence for  the physiological impor-
tance and pathological implications for this receptor in the 
bladder with mechanistic insight.
2 |  MATERIALS AND METHODS
2.1 | Animal and human tissue preparations
Young (2-5 months) and aging (24-36 months) male Dunkin-
Hartley guinea pigs (GPs, B&K Universal) were maintained 
under standard feeding conditions and used for experiments. 
GPs between 2 and 5  months old are mature young adults, 
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capable of breeding and are widely used in laboratory studies. 
From the age of 18 months, GPs begin to exhibit age-related 
structural and functional changes in both general and bladder-
specific physiology and therefore represent early old age.44-46 
Qualitative age-related urinary tract changes in humans, such as 
increased prostate growth, begin to emerge in GPs from 2 years 
and thereafter, indicating GPs above this age as a representative 
model for translational age-related studies.47,48 Animals were 
humanely culled by a schedule 1 procedure in accordance with 
the United Kingdom Animals (Scientific Procedures) Act of 
1986. All experiments were approved by the local ethics com-
mittee and followed UK home office regulations.
The urinary bladders were removed quickly dissected 
under microscopic guidance as previously described.49 To 
determine tissue layer-specific action, “full thickness” (FT), 
“smooth muscle only,” and “mucosal” strips were used. The 
mucosa (urothelium and suburothelium) was gently separated 
from underlying tissue by careful microdissection along the 
natural cleavage plane.
Human mucosal tissue biopsies were obtained by cystos-
copy from bladders of patients undergoing diagnostic endos-
copy. Samples were collected with informed patient consent 
and the approval of the National Research Ethics Committee 
(South East Coast—Surrey) in accordance with the Helsinki 
declaration. In patients with suspected tumors or cancer, blad-
der samples were taken from macroscopically normal areas. 
Samples from patients with no symptoms of OAB (non-OAB 
cohort, age 72 ± 2.3) and those from patients with symptoms 
of OAB (clinical diagnosis, frequency ≥ 8/day, urgency with 
or without urgency incontinence), diagnosed with idiopathic 
detrusor overactivity (IDO, OAB with no neurological abnor-
mality, OAB cohort, age 60 ± 5.0) were collected in the same 
way from Frimley Park Hospital (FPH), the Royal Surrey 
County Hospital (RSCH), and Medway Maritime Hospital 
(MMH). These mucosal biopsies were treated similarly to 
GP tissue and cut into longitudinal strips for experimentation.
Bladder strips were mounted within a customized hori-
zontal Perspex perfusion trough/organ bath with one end of 
the tissue tied to a fixed hook and the other to an isometric 
tension transducer with micromanipulator, allowing precise 
orientation of the tissue.49 Mounting of strips was performed 
under microscopic guidance to ensure accuracy and avoid ac-
cidental stretch and damage, which can generate ATP release. 
A water-jacket system was used to maintain experimental 
solutions and tissue at 37°C. The tissue preparations were su-
perfused with HEPES-buffered physiological Tyrode's solu-
tion (pH 7.4, 37°C) at a resting rate of 2 mL min-1 for at least 
45 minutes prior to experimentation to allow full tissue sta-
bilization. Both ATP release and contractile activity of tissue 
strips were measured (see below).
Isolated mucosal tissue was also used to prepare single 
urothelial cells by enzymatic dissociation for the purpose of 
intracellular Ca2+ measurement. Cells were dissociated using 
a collagenase type-1 (1.0 mg/mL Worthington Biochemical 
Corp, USA)-based enzyme mix dissolved in HEPES-buffered 
Ca2+-free Tyrode's solution.24
2.2 | Solutions
The HEPES-buffered Tyrode's solution used for preparation, 
incubation, and superfusion of tissue during experiments con-
tained (in mM) 132 NaCl, 4 KCl, 1.8 CaCl2, 1.0 MgCl2, 0.4 
NaH2PO4, 10 HEPES, 6.1 glucose, and 5 Na pyruvate (ad-
justed pH 7.4, osmolarity 311.2 mosM). For tissue isolation 
and storage, a nominally Ca2+-free modified Tyrode's solu-
tion was used, prepared as above with the omission of 1.8 mM 
CaCl2 and replaced by 1.8 mM MgCl2 to maintain the divalent 
cation concentration. For cell dissociation, the following were 
added; collagenase type I (1.0 mg/mL, Worthington biochemi-
cal, Lakewood, NJ), hyaluronidase type I-S (0.25 mg/mL) and 
type III (0.25  mg/mL), trypsin inhibitor type II-S (0.45  mg/
mL), and BSA (2.5 mg/mL). For Ca2+-free modified Tyrode's 
solution, the CaCl2 was substituted with additional MgCl2 
(total MgCl2: 2.8 mM) with the addition of EGTA (0.1 mM, 
[Sigma, UK]) to buffer any residual calcium to pCa of 8. The 
drugs and compounds used for interventions during physiolog-
ical experiments were dissolved in either ultra-pure water or 
DMSO (BDH, UK) and stored at −20°C as stock solutions of 
at least 1000 times their experimental concentrations, before 
final dilution on the experimental day. The experimental con-
centration of agonists was chosen based on preliminary work 
demonstrating a reproducible effect without causing significant 
desensitization, being above the EC50 but below the maximal 
effect. Experimental concentrations of antagonists were cal-
culated based on their affinity for receptors for predominant 
blockade, and where appropriate, to oppose the concentration 
of same-receptor agonist used, such that >95% of receptors 
were inhibited. RIPA lysis buffer for western blotting con-
tained final concentrations (in mM) 50 Tris-HCl, 150 NaCl, 2 
ethylene diamine-tetraacetic acid (EDTA), 50 NaF, 1% NP-40, 
1% sodium deoxycholate, protease inhibitor cocktail (“cOm-
plete, Mini, EDTA free PI cocktail” Roche, UK) in “ultra-
pure” distilled water, pH 7.5 ± 0.05. All chemicals were from 
Sigma unless otherwise stated.
2.3 | Measurement of ATP
Once mounted within the perfusion trough, tissue strips were 
left to stabilize in Tyrode's solution for 45 minutes prior to 
experimentation.49 Superfusate samples were collected from 
the sampling point (in close vicinity of the mucosa, 2/3rds 
downstream of the length of the tissue) using a micropipette 
tip under a microscope and immediately evaluated for ATP 
content. Samples were taken during the pre- and post-control 
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periods and during the drug intervention at 1, 3, and 5-min for 
short observations, followed by sampling at 5-min intervals 
thereafter for longer experiments. Mean ATP release before 
and after the drug intervention was taken as the baseline ATP 
release. Mean ATP release across all sampling times during 
the drug intervention was taken as drug effect and expressed 
as a percentage difference from the baseline. Appropriate 
controls were carried out for solvents used. For stretch experi-
ments, tissue was mechanically stretched to 150% of the orig-
inal length for 30 s before the tissue was relaxed to its resting 
length. These parameters were chosen based on preliminary 
work that demonstrated a significant and reproducible stretch-
induced ATP release. Superfusate was sampled at 30 s, 1 min-
utes, 2 minutes, and 3 minutes after initial stretch. Sampled 
superfusate was immediately assessed for ATP content using 
the ATP-dependent bioluminescent “Luciferin-Luciferase” 
assay (Sigma, UK).49 Luminescence intensity was read using 
an LKB Wallac 1250 luminometer. Appropriate control read-
ings of reagents and chemicals were also taken to account for 
any background luminescence.
2.4 | Measurement of isometric tension
For appropriate interventions, the magnitude of contraction 
elicited by an agonist was determined. Tissue strips were 
mounted within the perfusion trough and tied to a force-dis-
placement transducer coupled with a bridge-amplifier and iso-
metric tension measured and recorded as described before.10 
As with ATP measurement, tissue preparations were continu-
ously superfused with HEPES-buffered Tyrode's solution and 
drug interventions were introduced via this superfusate.
2.5 | Measurement of intracellular Ca2+
Intracellular Ca2+ concentration ([Ca2+]i) was measured by 
epifluorescence microscopy using the fluorescent Ca2+ indi-
cator dye Fura-2 as described previously.49 The cell suspen-
sion was placed in a Perspex perfusion dish mounted on the 
stage of an inverted microscope maintained at 37°C. After 
attachment, cells were superfused with a continual flow 
of oxygenated Tyrode's solution at approximately 2  mL/
min−1. Cells were then visualized using the microscope and 
the cell of interest was alternately illuminated with 340 nm 
and 380 nm excitation wavelengths at 50 Hz. Emitted light 
between 410 nm and 510 nm split and selected by dichroic 
mirrors and filters was then collected by a PMT tube/CCD 
camera. Single cells were challenged with 100  μM ATP 
or 1 μM GSK1016790A. The ratio of the emitted fluores-
cence intensities at these two excitation wavelengths was 
converted into intracellular [Ca2+] values using a previously 
described in vitro calibration method.50,51
2.6 | Immunohistochemistry
Sections of full bladder wall were embedded in OCT 
(Bright Instrument LTD, UK), snap-frozen in liquid ni-
trogen (LqN) and cut into 10  μm thick sections through 
the transverse plane using a precooled cryostat (Hyrax 
C25, Zeiss, Germany [−22°C]), before being immediately 
mounted onto poly-L-lysine coated slides. Each section 
was viewed under a light microscope to ensure structural 
integrity and presence of all tissue types. Cryosections 
were fixed in precooled methanol for 5 minutes at −20°C, 
before phosphate-buffered saline (PBS, Oxoid) washes. 
Sections were blocked with 1%BSA/PBS solution for 
1  hour at room temperate and incubated over-night at 
4°C in rabbit anti-TRPV4 polyclonal primary antibody 
(2.0  μg/mL, Alomone, Israel [AC-034]; 1:200). Bound 
primary antibody was detected with Alexa 568-conju-
gated Goat anti-Rabbit IgG (Thermo Fisher Scientific [A-
11011]). A nuclear stain (TO-PRO3 [Molecular Probes, 
Netherlands]) was used to aid with visualization of tissue 
morphology. For dual staining, TRPV4 (Abcam, 1:500) 
and cytokeratin 18 primary (mouse monoclonal, Sc-
51582, Santa Cruz, 1:200) antibodies were used to show 
urothelial co-localization and TRPV4 and ɑ-smooth mus-
cle actin (mouse monoclonal, A-2547 Sigma, 1:100) pri-
mary antibodies used for smooth muscle co-localization; 
secondary antibody: Alexa 488-conjugated donkey anti-
mouse IgG (A21202, Thermo Fisher Scientific, 1:1000). 
Stained sections were visualized at 40× magnification 
(oil-emersion lens) using a Zeiss LSM510 META laser 
scanning confocal microscope and images were subse-
quently analyzed using Axovision LSM 510 Meta soft-
ware. Appropriate filters and light paths were employed to 
separate the transmitted excitation light from the emission 
light, omit any autofluorescence and detect only the de-
sired emission wavelength of each specific antibody/stain 
(alexa-568nm [emission 603], TO-PRO3 642  nm [emis-
sion 661]). Appropriate primary antibody omission and 
peptide antigen pre-absorption controls were performed to 
confirm antibody specificity. For each animal bladder in-
vestigated (“n number”), three positively stained sections 
were examined to confirm expression of TRPV4 through-
out that bladder, alongside a secondary control section. 
TRPV4 fluorescence was quantified for each image using 
ImageJ software (version 2, NIH, USA). An area of inter-
est was defined using the *oval* tool (consistent area of 
435.29 units) and this was used to measure the mean pixel 
density of three different areas of each tissue type within 
any given image. The mean pixel density for secondary 
controls was subtracted from positively stain sections to 
provide a final value for pixel density, representing the 
strength of TRPV4 staining, allowing relative expression 
to be compared between tissues.
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2.7 | Western Blot
Separated tissue samples (“mucosal” or “smooth muscle”) were 
snap-frozen and homogenized in liquid nitrogen (LqN) using 
a pre-cooled pestle and mortar. The homogenate powder was 
lysed in an appropriate volume of RIPA buffer and sonicated 
at 100Amp using a VC130PB ultrasonic processor (Sonics 
& Materials Inc, USA) for 30 seconds to release intracellular 
components. Samples were centrifuged (100 g, 2 minutes, 4°C) 
and the protein concentration of supernatants determined using 
a colorimetric protein assay kit (DC protein assay, BioRad, 
UK). Supernatants were then mixed in a 1:1 ratio with Tris-
glycine-SDS sample buffer (Novex, Thermo Fisher, USA) and 
incubated at 95°C for 5 minutes on a hot plate to fully resolve 
the lysate. Whole rat brain lysate (RBL) (10 μg) was used as 
positive control for antibody binding. Tissue lysates (30 μg) 
were loaded and electrophoretically resolved on precast gels 
(8%-16% Mini-PROTEAN TGX, BioRad, UK) and then trans-
ferred to a 0.45 μm nitrocellulose membrane (Novex, Thermo 
Fisher, USA) using a BioRad blotting system. Membranes were 
probed with primary antibodies for 1 hour at room tempera-
ture and the bound antibody detected using IRDye-conjugated 
secondary antibody (LI-COR Biosciences, Germany). The 
signal was detected and analyzed using an Odyssey CLx in-
frared imaging system (LI-COR, Germany). Each membrane 
was probed for β-actin (New England Biolabs, USA) to serve 
as a loading control. Two anti-TRPV4 antibodies were tested 
(Alomone Labs, Israel, 1:200; Abcam, UK, 1:1000).
2.8 | Lucigenin chemiluminecence
Superoxide (O2−) production by bladder tissue lysates or 
whole-tissue pieces was measured using lucigenin-enhanced 
chemiluminescence. For whole-tissue lysates, FT bladder 
strips were incubated in either Tyrode's or Tyrode's with 
GSK (1 μM) for 30 minutes at 37°C. Strips were snap frozen 
and processed into tissue lysates in the same way as western 
blotting (LqN homogenization and sonication), in a modi-
fied Hanks' Balanced Salt solution (0.8 mM MgCl2, 1.8 mM 
CaCl2). Protein concentrations (2-20 μg/μL) of each sample 
were determined using a Bradford-based protein assay kit 
(Bradford Assay dye, BioRad, UK). For whole-tissue pieces, 
freshly obtained bladders were dissected into small (1-3 mg) 
pieces of separated mucosa, smooth muscle or FT tissue. On 
the day of experiment, either a whole-tissue piece or 25 μL of 
tissue lysate was transferred to an opaque 96-well plate with 
5 μM lucigenin containing buffer and the basal luminescence 
measured by a luminometer (BMG Lumistar, Germany). The 
substrate NADPH (25 μM) was then added and sample lumi-
nescence recorded. The cell-permeable O2− scavenger Tiron 
(10 mM) was then added and luminescence measured for a 
final time. Sample luminescence was corrected to protein 
concentration and O2− production expressed as median arbi-
trary light units per minute (MLU/min).
2.9 | Data analysis
Data are expressed as median ± interquartile range (int. range), 
or mean ± SEM, where n denotes the number of bladders as-
sessed, unless otherwise stated. All data are normalized to tis-
sue mass or protein concentration unless otherwise stated. All 
data have been tested for normality using D'Agostino-Pearson 
omnibus test. For non-parametric data, Mann-Whitney test 
(unpaired, non-parametric Student's t test) was used to ex-
amine two unpaired data sets of unknown distribution. A 
Wilcoxon matched-pairs signed rank test was used to analyze 
paired data sets, for example comparing two different inter-
ventions performed on the same bladder strip. A Spearman's 
rank correlation was used to test the association between 
two variables. For normally distributed data sets, parametric 
tests were used to test the difference between two data sets (t 
tests) and among multiple data sets (ANOVA and post-hoc 
pair-wise comparisons). The null hypothesis was rejected at 
P < .05, with the level of significance indicated by *P < .05, 
**P < .01, and ***P < .001. All statistics were performed 
using raw data, unless comparing the relative effects of two 
different interventions. However, graphs display normal-
ized data for clear comparisons. All statistical analysis was 
performed using Microsoft Excel (2010, version 14.1.6) and 
GraphPad Prism (2015, version 6.07, GraphPad Software).
3 |  RESULTS
3.1 | Protein expression of TRPV4 in 
guinea-pig bladder tissues
Evidence for the expression of TRPV4 receptors was first 
sought in ex vivo bladder tissues. Immunofluorescence stain-
ing qualitatively demonstrated the existence of TRPV4 recep-
tors and its distribution in different tissue layers in the bladder 
wall. Western blot measurement determined the specific mo-
lecular weight band of TRPV4 proteins and its quantification.
3.1.1 | Immunofluorescence
GP bladders showed TRPV4 immunoreactivity through-
out, with strongest expression in the urothelium (n = 10) and 
lower, similar levels in both the suburothelium (n-10) and 
DSM (n = 7, Figure 1A). Specificity of the antibody to TRPV4 
was confirmed by performing blocking peptide pre-absorption 
controls on four of the GP bladders assessed (one representa-
tive image shown, Figure 1B). TRPV4 immunoreactivity was 
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quantified for each tissue and expressed as mean pixel density 
(Figure 1C). Primary antibody omission controls (representa-
tives shown in figures) were performed to determine the level 
of background from non-specific secondary antibody binding. 
Positive control of brain tissue was also presented (1D). TRPV4 
immunoreactivity was significantly greater in urothelium than 
in suburothelium and DSM. Co-staining of cytokeratin 18 
(urothelium) and ɑ-smooth muscle actin (smooth muscle) with 
TRPV4 confirmed TRPV4 expressions in the urothelial layer 
and smooth muscle layer (1E). These data show that native 
bladder tissues express abundant TRPV4 receptors across the 
bladder wall with the highest density in the urothelium.
F I G U R E  1  Immunohistochemical localization of TRPV4 in GP bladder tissues. A, Representative images of TRPV4 (Alomome) IHC in GP 
and human cryosections. TRPV4 fluorescence (red) was detected in both GP and human mucosa and smooth muscle tissue; Insets: control using 
only the secondary antibodies without TRPV4 primary antibody (anti-rabbit IgG Alexa 568, life technologies). Nuclei are stained with TO-PRO3 
(Cy5; blue; Invitrogen). U, urothelium; SU, suburothelium; L, lumen. Scale bars represent 50 µm in all images. B, Representative peptide control 
for Alomone anti-TRPV4 primary antibody. C, Quantitative analysis of TRPV4 fluorescence. Similar expression patterns observed in both species, 
with highest fluorescence in the urothelium. Median values [25%, 75%], GP urothelium and suburothelium n = 10, smooth muscle n = 7; human 
urothelium and suburothelium n = 4, smooth muscle n = 3, *P < .05, Wilcoxon's. D, Cerebral cortex slice TRPV4 positive control, left control 
with no primary Ab, right TRPV4 staining; E, Co-staining of TRPV4 with cytokeratin 18 and ɑ-smooth muscle actin in urothelium (i) and smooth 
muscle layer (ii)
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3.1.2 | Western blot
To complement the immunostaining data, Western blot was 
used to identify the specific band for the TRPV4 protein mol-
ecule and determine its quantity. TRPV4 expression was de-
tected in separated GP mucosal and smooth muscle lysates, 
run against RBL positive control tissue. Two anti-TRPV4 
Abs were used to corroborate results and confirm reliability 
(Alomone, Israel and Abcam, UK). For both antibodies, a 
single band was observed close to the predicted molecular 
weight of TRPV4 (98 kDa), between 95 and 100 kDa, for both 
RBL and bladder tissue lysates (Figure 2A,B). Quantification 
by densitometry revealed a significantly higher expression of 
TRPV4 in mucosal tissue than that in smooth muscle when 
using either Ab (Figure 2C). Mucosal TRPV4 expression was 
approximately sixfold higher compared to smooth muscle 
when probed with the Abcam antibody and fourfold higher 
with the Alomone antibody. The results obtained using one 
primary antibody were not significantly different from the 
other, indicating strong reliability. The data show specific 
TRPV4 protein expression in bladder tissues and signifi-
cantly higher levels of TRPV4 expression in the urothelial 
tissue.
3.2 | Effect of TRPV4 activation on ATP 
release and contractile activity in the bladder
The evidence for the function of TRPV4 receptors and the 
mode of action was examined next. Two key physiological 
functional outputs, ATP release from the urothelial layer and 
the contraction of the smooth muscle, were examined in dif-
ferent ex vivo bladder tissue preparations by selective activa-
tion of TRPV4 with agonist GSK1016790A (GSK).
3.2.1 | Effect of activating TRPV4 receptor 
on bladder functional outputs
The role of TRPV4 receptor in ATP release and contractile 
function of the bladder was assessed by three concentrations 
of GSK (0.3, 0.5, and 1 μM) (Figure 3A). GSK application 
consistently evoked significant contractions in bladder tissue 
preparations. 1 μM GSK produced significantly stronger and 
more reproducible contractions in FT strips than lower con-
centrations (proportion of successfully evoked contractions; 
0.3  μM—20%, 0.5  μM—25%, 1  μM—90%, Figure 3A(i)). 
Mucosal contractions were not observed at any dose. All 
F I G U R E  2  Expression levels of TRPV4. A, GP tissue; Representative western blot of TRPV4 (98 kDa), Abcam primary antibody. B, GP 
tissue; Representative blot of TRPV4 (98 kDa), Alomone primary antibody. β-actin loading controls (42 kDa) shown in blot below dotted blue 
line. (RBL: rat brain lysate Muc: mucosa, SM: smooth muscle). Membrane was cut at 55 kDa (dashed blue line) and each half probed with the 
appropriate antibodies. C, Quantified data of TRPV4 expression by densitometry, normalized to its loading control. Samples duplicated and 
averaged. Results for each tissue type are similar when using either primary antibody; mucosal lysates have significantly higher TRPV4 expression 
than in smooth muscle lysates with either primary antibody. No significant difference between antibodies for either tissue type. Median values 
[25, 75], Abcam; n = 5, Alomone; n = 8, Mann-Whitney. D, Western blot of human mucosal biopsies. Three of the four samples assessed have a 
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doses evoked significant ATP release from separated mu-
cosal and FT strips, with no significant difference between 
any (Figure 3A(ii)). As 1 μM GSK is the only tested concen-
tration capable of evoking both reproducible ATP release and 
contractions in bladder strips, and is far below that which may 
have effects on other receptors, this concentration was used 
for subsequent functional experiments. The force of 1  µM 
GSK-induced bladder contractions did not coincide with the 
level of ATP release as demonstrated in Figure 3B, with a 
correlation coefficient rs value of 0.02374. This suggests that 
TRPV4-activated urothelial ATP release and smooth muscle 
contractions from the bladder are independent processes and 
their down-stream pathways are also different.
Contractions evoked by GSK (1 μM) in FT strips were of 
similar magnitude to those evoked by the major physiological 
neurotransmitter cholinergic agonist carbachol (50 μM). The 
specificity of muscarinic activation by carbachol was con-
firmed in our control experiment by the complete block by 
muscarinic antagonist atropine and no effect of the sodium 
channel blocker TTX which excludes any measurable contri-
bution from possible TTX sensitive action potential induced 
neuronal release of acetylcholine under these conditions. 
However, GSK was not capable of evoking contractions in 
mucosal sheets, whereas carbachol was able to cause the con-
traction 24 (Figure 3C). Figure 3D shows the representative 
TRPV4-induced contractile response in both mucosa and FT 
strips next to a typical carbachol trace. GSK-induced contrac-
tions in FT are sustained despite continuous perfusion wash-
out, unlike transient carbachol-induced contractions. The 
results suggest that TRPV4 receptors are capable of generat-
ing strong muscle contractions in the bladder, but the mode 
of action is different from the major physiological receptor—
muscarinic receptors.
3.3 | Mode of action and underlying 
mechanisms for TRPV4 activation
3.3.1 | Tissue origin of ATP release
To identify the tissue origin of ATP release in the bladder 
wall, the ATP release was examined in the smooth muscle 
F I G U R E  3  Effects of GSK-induced TRPV4 activation on GP bladder functional outputs. A(i), Median force of mucosal and full-thickness 
contractions generated by various GSK concentrations. Significantly stronger contractions evoked by 1 μM. A(ii), Corresponding median ATP 
release from same bladder strips. All concentrations significantly increased—ATP release (0.3 μM n = 10; 0.5 μM n = 8; 1 μM n = 18); control: 
107 ± 39 pmoles/g tissue/min. B, Relationship between GSK1016790A-induced contractions and ATP release. No correlation observed between 
the contraction and level of ATP release in GP FT strips. Spearman correlation coefficient rs of 0.02374, n = 18. C, Median values of GSK-induced 
contractions (n = 8), with record of single 50 μM carbachol (CCh) contraction for reference (n = 1) (note Log2 y axis). D, Record of sustained 
contraction induced by 1 μM GSK in FT strip (i) (and mucosal strip) and transient CCh-induced contraction in FT strip. Median values [25%, 75%]. 
A(ii), drug intervention vs. control (basal levels [BL]) compared using Wilcoxon's, *P < .05; All graphs: data sets compared using Mann-Whitney
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and compared to those in mucosa and full-thickness bladder 
strips. GSK evoked contractions in 70% of mucosa-denuded 
smooth muscle strips with similar magnitude to FT strips, sup-
porting that GSK-induced contraction was mainly from the 
smooth muscle. However, the significant ATP release seen 
in the full-thickness bladder tissue was lost, with only 16% 
of strips releasing ATP beyond basal levels (Figure 4A,B). 
Figure 4C shows the absolute quantity of ATP released from 
bladder strips in response to GSK (expressed as ρmoles/g tis-
sue/min). Significant ATP release was evoked in both mucosa 
and FT tissue, but not in mucosa-denuded smooth muscle. 
Mucosa released significantly more ATP per gram tissue than 
FT, implying the tissues underlying the mucosa in the FT strip 
are insignificant with regards to ATP release. Additionally, 
mucosa released significantly more basal ATP per unit tissue 
than both denuded smooth muscle and FT tissue (Figure 4C). 
This, and the fact that denuded smooth muscle is incapable 
of releasing significant amount of ATP in response to GSK, 
implies that most of, if not all GSK-induced ATP release is 
from the mucosa and hence of urothelial origin.
3.4 | Mechanisms underlying TRPV4-
induced mucosal ATP release
3.4.1 | Control experiment
The majority of the experiments that follow required three 
repeated exposures of tissue to 1  μM GSK, with an hour 
recovery period between each and the second including an 
F I G U R E  4  Effects of denuding GP bladder on GSK-induced ATP release and contraction. Shown alongside mucosa and FT strips for 
comparison. A, Median force of tissue contractions generated by 1 μM GSK. No significant difference between FT and denuded smooth muscle 
strips. B, Corresponding median ATP release from same bladder strips. Denuded smooth muscle does not release ATP in response to GSK 
(n = 10). C, ATP release from same tissue strips expressed in ρM/g tissue/min. Significant ATP release from mucosa and FT, but not denuded 
tissue. GSK-induced ATP release from mucosa was significantly greater than from FT (not shown). Basal ATP release from mucosa was 
significantly greater than basal ATP release from denuded and FT tissue (direct comparision plot not shown). Basal release from FT was not 
different to denuded. Median values [25%, 75%], mucosa and FT n = 8, denuded n = 10, *P ≤ .05, Wilcoxon's for drug intervention vs. control. 
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antagonist. The following control experiment assessed the re-
producibility of ATP release in response to three successive 
exposures to GSK without antagonist. All three exposures 
significantly enhanced ATP release in both mucosal and FT 
bladder preparations, with no significant difference between 
any (Figure 5). A contraction was evoked with the first ex-
posure, however the following exposures were incapable of 
eliciting further contractions suggesting possible desensitiza-
tion of TRPV4 response on the smooth muscle and this was 
observed throughout all similar experiments in this study.
3.4.2 | Effect of TRPV4 blockade
5 μM HC-067047 (HC), a selective TRPV4 antagonist, was 
chosen for predominant blockade (>90%) of TRPV4 recep-
tors in the presence of 0.5µM GSK based on binding to the 
same receptor by two ligands with known affinities, while 
both agents were still within TRPV4-receptor-specific con-
centrations. The ATP release triggered by GSK (0.5  μM) 
was significantly reduced by HC to near basal levels in 
both tissue types (Figure 6A), demonstrating high specific-
ity of GSK to TRPV4. A further test on 1  µM GSK with 
10  µM HC also largely abolished the GSK-induced ATP 
release as well as GSK-induced muscle contractions, prov-
ing specificity of 1 µM GSK on urothelial ATP release and 
smooth muscle contractions (Figure 6D). HC (at a lower 
concentration in the absence of GSK, 1  µM) also signifi-
cantly reduced basal ATP release from mucosa (Figure 6B). 
Basal ATP release was significantly reduced after 10 minutes 
exposure. These data suggest that TRPV4 channels are open 
in the intrinsic environment of bladder tissues, especially in 
the urothelium and hence the functional importance of this 
receptor in controlling ATP release from the bladder tissues.
3.4.3 | Specific pathway for TRPV4-induced 
ATP release
The two fundamental pathways for ATP release from the 
cell cytoplasm to extracellular space (conductive and exocy-
totic52,53) were further investigated for TRPV4-induced mu-
cosal ATP release. The pannexin/connexin channel inhibitor 
carbenoxolone (100 μM) significantly reduced GSK-induced 
ATP release in both tissue types by approximately 90% 
(Figure 7A). Brefeldin A (10  μM), an inhibitor of vesicu-
lar transport-mediated ATP release, had no effect on GSK-
induced (TRPV4-activted) ATP release in either tissue type 
(Figure 7B). These findings suggest that the observed ATP is 
released via conductive pathways, with little or no involve-
ment of vesicular transport.
Various other channels and signaling molecules were 
investigated to further elucidate the pathway underlying 
TRPV4-mediated ATP release. Limited previous literature 
suggests that ATP release through hemichannels is associ-
ated with activation of Cl− channels.54 Therefore, the ef-
fect of NPPB (Ca-activated Cl channel blocker, 100 μM) 
was investigated; however, this was ineffective in reducing 
GSK-induced ATP release (Figure 7C). Genistein (selec-
tive protein tyrosine kinase inhibitor, 100 μM), however, 
suppressed GSK-induced ATP release to below basal lev-
els in both tissue preparations (Figure 7D), suggesting a 
role for tyrosine protein kinases in either the downstream 
signaling pathway for TRPV4-mediated ATP release 
or in the modulation of the activity of TRPV4 channels 
themselves.
3.4.4 | Role of Ca2+ in TRPV4-mediated 
ATP release
The Ca2+ dependence of TRPV4-mediated ATP release 
was explored by removal Ca2+ in a Ca2+-free extracellu-
lar environment. The stimulating effect of 1 μM GSK on 
ATP release was abolished in the absence of extracellular 
Ca2+ (mucosa: 90% reduction, FT: 70% reduction; Figure 
8A; Ca2+-free modified Tyrode's solution used is described 
F I G U R E  5  Effect of repeated exposure to GSK on GP bladder 
functional outputs. A, Force of contractions generated by three 
successive exposures to 1 μM GSK (1-hour recovery period between 
each). No contractions observed in mucosa, a large contraction evoked 
in FT with first exposure, which is lost (significantly less) with 
successive exposures. B, Corresponding ATP release from same strips. 
All exposures significantly increase ATP release from basal levels 
(115 ± 27pmoles/g tissue/min). No significant difference in ATP 
release observed between successive exposures. Median values [25%, 
75%], n = 10, *P < .05, Wilcoxon's
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F I G U R E  6  Effect of TRPV4 antagonism on ATP release. A, HC (5 μM) significantly reduced ATP release triggered by GSK (0.5 μM, 
214 ± 82/pmoles/g tissue/min) in GP strips (n = 7; *P < .05). B(i), 1 μM HC significantly reduced basal ATP release in GP mucosal and FT strips, 
relative change (%). B(ii), Effect of HC on basal ATP release; data expressed as median release/g tissue/min. (n = 8; *P < .05, **P < .01); C(i), 
HC (1 µM) reduces basal ATP release in human mucosal biopsies (n = 7). C(ii), Effect of HC on basal ATP release in human mucosal samples; 
data expressed as % control and release/g tissue/min (n = 8; *P < .05). D, 10 µM HC also effectively inhibited 1 µM GSK-induced ATP release (i) 
(n = 5) and smooth muscle contraction: (ii) (n = 4). Mean ± SEM; paired t test
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in Solutions). This suggests a key role of Ca2+ in mediat-
ing ATP release from the urothelium. The role of Ca2+ in 
TRPV4 activation was further examined in freshly isolated 
urothelial cells. Live-cell Ca2+ imaging in single urothelial 
cells demonstrated a large rise in intracellular Ca2+ in re-
sponse to TRPV4 activation (Figure 8B(i)). The averaged 
data from seven bladders revealed that TRPV4 activation 
(GSK, 1 μM) significantly raised [Ca2+]i from resting lev-
els, providing further evidence for the involvement of Ca2+ 
in TRPV4-mediated signaling (Figure 8B(ii)). Importantly, 
the magnitude of TRPV4 activation induced Ca2+ rise is 
much greater than that induced by the major physiologi-
cal activator ATP in the same cells (Figure 8B(iii)). This 
demonstrates that Ca2+ response is a key signaling pathway 
for TRPV4 activation and also the functional importance of 
TRPV4 receptors in urothelial function. Furthermore, the 
Ca2+ rise by TRPV4 activation has a long duration and is 
sustained after removal of the agonist, which reveals a long 
open state of the channel (Figure 8B(i)). Thus, these data 
support that extracellular Ca2+ entry, resulting in increased 
intracellular Ca2+, is involved in TRPV4-mediated ATP 
release.
3.4.5 | Effect of TRPV4 inhibition on 
stretch-evoked ATP release
The question as to what extent TRPV4 is involved in stretch-
induced ATP release in intact bladder tissue was also ex-
amined. Mucosal and FT strips (5-6  mm) were stretched 
to 150% of their original length for 30  seconds using a 
micromanipulator, and ATP release was measured during 
and after stretch (parameters based on preliminary work). 
Strips were successively stretched three times, with 1-hour 
recovery periods. A control experiment assessed the viability 
and reproducibility of this protocol (Figure 9A). 150% stretch 
evoked significant release of ATP at 30 seconds and 1 minute 
after initial stretching, which subsided after 2 minutes. These 
dynamics of ATP release were reproducible for a second and 
third stretch. The increased ATP release at 30 seconds and 
1 minute in both tissue preparations during all three stretches 
have a P value < 0.05 compared to controls for n = 5 and 
there was no statistical difference in stretch-induced ATP re-
lease from the tissues between different runs of sequential 
stretches. This information was sufficient to perform ex-
periments using antagonists to assess the role of TRPV4 in 
stretch-induced ATP release.
TRPV4 was antagonized using HC (1 μM) during the 
second stretch. Tissue stretch during inhibition of TRPV4 
with HC still raised ATP release above basal levels in both 
tissue preparations at 30  seconds and 1  minute (Figure 
9B(i)). However, the stretch-evoked ATP release during 
TRPV4 inhibition was significantly less than that evoked 
without inhibition at 30 seconds in both tissue preparations 
and at 1  minute also in FT (Figure 9B(ii)). These values 
translate to approximately a 50% reduction in the stretch-
evoked ATP release when inhibiting TRPV4 (mucosa; 
30  seconds—61% reduction, 1  minute—46% reduction, 
FT; 30  seconds—49% reduction, 1  minute—70% reduc-
tion). This suggests that TRPV4 is partly but not exclu-
sively responsible for the stretch-induced ATP release from 
the bladder mucosa.
F I G U R E  7  Effect of various 
inhibitors on GSK-induced ATP release 
from GP bladder strips. A, Carbenoxolone 
(100 μM; connexin/pannexin channel 
blocker) significantly reduces GSK-
induced (n = 9). B, Brefeldin A (10 μM; 
vesicular transport inhibitor) has no effect 
on GSK-induced ATP release. C, NPPB 
(100 μM; inhibits Ca2+-sensitive chloride 
currents) has no effect on GSK-induced 
ATP release (n = 6). D: Genistein (100 μM; 
selective protein tyrosine kinase inhibitor) 
significantly reduces GSK-stimulated 
ATP release (n = 8). Median [25%, 75%], 
Wilcoxon's. Control: 282 ± 72 pmoles/g 
tissue/min
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3.5 | Effect of TRPV4 activation on bladder 
reactive oxygen species (ROS) production
Inflammation and oxidative stress are closely related, and 
both participate in aging and pathogenesis of many chronic 
conditions. The ability of TRPV4 channel to generate ROS 
was thus investigated. Superoxide (O2−) production was 
measured using lucigenin chemiluminescence in homog-
enized GP FT strips after pre-treatment with either control 
Tyrode's solution or 1  μM GSK. In the absence of added 
agents, basal luminescence intensity in FT tissue lysates was 
minimal and did not differ between control and treated groups 
(MLU/0.1  mg protein: Tyrode's con—35 [30, 55], GSK—
46 [39, 122]; Figure 10B). Addition of NADPH (100 μM) 
significantly increased the luminescence intensities from 
basal levels in both groups, representing NADPH-dependent 
ROS production. After addition of the O2− scavenger Tiron 
(10 mM), NADPH-dependent ROS production was signifi-
cantly suppressed, suggesting most of NADPH-dependent 
ROS production is superoxide. Addition of Tiron enabled 
the proportion of ROS composed of O2− to be determined. 
This revealed that activation of TRPV4 receptors by pre-
treatment with GSK significantly enhances O2− production 
in bladder tissue above that of control tissue (MLU: Tyrode's 
control—70 [33, 123], GSK—136 [44, 219]; Figure 10C(ii)). 
TRPV4-induced O2− production is a novel mode of action 
which may affect bladder signaling and alter oxidative stress 
levels with further downstream implications.
F I G U R E  8  Role of Ca2+ in GSK-induced ATP release from GP bladder tissue. A, Removal of Ca2+ from Tyrode's superfusate significantly 
reduces GSK-stimulated (1 μM) ATP release (Median, [25%, 75%], n = 8, Mann-Whitney)); control: 166 ± 55 pmoles/g tissue/min. B(i), GSK 
(1 μM) generates a Ca2+ transient (left) in a freshly isolated single urothelial cell from GP bladder; ATP-induced Ca2+ transient (right). B(ii), 
Averaged data; GSK (1 μM) evokes a significant rise in [Ca2+]i, (mean ± SEM, n = 7, P < .05). B(iii), Averaged data; GSK (1 µM) induced [Ca2+]i 
rise (n = 9) vs ATP (100 µM) induced[Ca2+]I, (n = 14); P < .05, Mean ± SEM, unpaired t test
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3.6 | Effect of aging on TRPV4 
expression and function
Recent evidence suggests that aging affects urothelial func-
tion. The effect of aging on TRPV4 expression and function 
was thus examined.
3.6.1 | TRPV4 protein expression
The representative blot in Figure 11A shows clear bands at 
the same molecular weight (98 kDa) as the positive control, 
proving presence of TRPV4. Visual inspection of the band 
intensity and size shows clearly that the expression of TRPV4 
is greater in aging tissue than in the young. Quantification by 
densitometry further revealed a significantly greater median 
TRPV4 expression (eightfold) in aging mucosa than young (ar-
bitrary units normalized to loading control aging: 42.9 [25.7, 
75.6], young; 5.8 [2.1, 14.3]) and (16-fold) in smooth muscle 
(aging; 13.5 [10.1, 28.3], young; 0.8 [0.6, 3.4]; Figure 11B). 
These data suggest that TPPV4 expression is up-regulated 
during aging.
3.6.2 | TRPV4-induced contractility and 
ATP release
GSK was able to trigger ATP release from bladder mucosa 
in aging bladders. There was no significant difference in the 
quantities of ATP released from the mucosa per gram of tis-
sue in response to TRPV4 activation between age groups 
(ρmoles/g tissue/min: Young, con; 47 [38, 63], GSK; 105 
[45, 379]; Aging, con; 72 [37, 134], GSK; 96 [73, 543]; 
Figure11C). Similarly, contractions evoked by GSK in 
young and aging FT strips were not significantly different 
(not shown).
F I G U R E  9  Effect of TRPV4 inhibition on mechanical stretch-induced ATP release from GP bladder tissues. A, Control experiment 
(n = 5). Mechanical stretch evoked significant ATP release at 30 seconds and 1 minute during each repeated stretch. The ATP release subsided 
after 2 minutes. No significant difference was observed in 30-second ATP release and 1-minute ATP release between the stretches. B, Stretch-
induced ATP release during inhibition of TRPV4 receptors with HC-067047 (second stretch during protocol). B(i), Mechanical stretch stimulated 
significant ATP release (n = 11); control: 111 ± 28 pmoles/g tissue/min. B(ii), Stretch-induced ATP release with (dark grey bars) or without (light 
grey bars) inhibition of TRPV4 (HC-067047; 1 μM). TRPV4 inhibition significantly attenuates stretch-induced ATP 30 seconds after mechanical 
stimulation (n = 11, Light grey bars: Averaged ATP release from pre- and post-stretch interventions. Dark grey bars: ATP release from middle 
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3.7 | Relevance to human conditions
To show the relevance of the above findings from animal 
tissues to human conditions, evidence for the expression of 
TRPV4 proteins and its functional role were examined in 
freshly obtained human bladder mucosal biopsies.
3.7.1 | Evidence of TRPV4 expression in 
human bladder tissues
Immunofluorescence staining shows positive staining for 
TRPV4 antibody. This was observed in the four human 
biopsies assessed (Figure 1A). The positive immunoreactiv-
ity was observed across all layers of the bladder wall. TRPV4 
immunoreactivity was greater in urothelium than suburothe-
lium and DSM for each of the four biopsies examined, simi-
lar to data obtained from GP bladder tissues. These data show 
that TRPV4 proteins are expressed in the bladder wall, and 
the urothelium has the highest level of expression in human 
bladders.
Western blot measurement was further performed in 
human tissue. TRPV4 expression was detected in three of the 
four human mucosal biopsies examined (non-OAB cohort). 
The same RBL positive control sample used for GP blots 
was used here, providing reassurance of correct band size. 
Once again, clear bands were observed at the same molecular 
FIGURE 10  Effect of 1 μM GSK on ROS and O2− production in homogenized GP bladder tissue. A, Kinetics of ROS production over experimental 
time-course. 0-15 minutes; basal ROS production, 15-30 minutes; ROS production after 100 μM NADPH, 30-45 minutes; ROS production after 5 mM 
tiron (O2− scavenger; n = 10). B, Median light units (MLU) averaged across 15-minute period of each treatment. No significant difference observed 
between groups during any treatment. NADPH (100 μM) significantly enhanced ROS from basal levels in both tissues (**). ROS production in the 
presence of Tiron was significantly less than during NADPH treatment (††), but still significantly greater than basal levels (**; n = 10). C, Tiron-sensitive 
(inhibited) component (O2−-specific production): (i): Paired dot plot--difference in O2− production between control and GSK-treated FT strips from each 
bladder investigated (n = 10). (ii): Averaged O2− production. Pre-treatment with 1 μM GSK (TRPV4 activation) stimulates significantly greater O2− 
production than controls (n = 10). Median values [25%, 75%], *P ≤ .05, **P ≤ .01, Wilcoxon's
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weight (~98 kDa) as the positive control for three of the four 
mucosal lysates assessed, thereby confirming presence of 
TRPV4 (Figure 2D) in human bladder mucosa.
3.7.2 | The functional role of TRPV4 
receptor and its regulation in human conditions
Further to the demonstration of TRPV4 expression in 
human bladder tissues, the function of TRPV4 receptor was 
examined.
Effect of TRPV4 activation on ATP release and 
contractions in human mucosal biopsies
The two key physiological outputs for bladder mucosa and 
smooth muscle, ATP release and muscle contractility, respec-
tively, were investigated when TRPV4 receptor was selec-
tively stimulated with the specific activator GSK1016790A.
GSK (1  μM) significantly enhanced ATP release, with 
an onset 3  minutes after initial exposure, with the peak at 
10 minutes in non-OAB biopsies (n = 10) (Figure 12A). This 
response is slightly delayed compared to GP tissue, which 
evokes ATP release after 1 minute. However, the overall pos-
itive response was similar to GP tissue.
Mucosal sheets did not produce contractions in response 
to GSK (Figure 12E). These data show TRPV4 activation 
does not cause mucosal contractions in human tissue, consis-
tent with findings in GP bladders.
Effect of TRPV4 inhibition on basal ATP release
TRPV4 inhibition (HC, 1µM) in non-OAB human mucosa 
significantly reduced basal ATP release. This demonstrates 
that there is intrinsic activity of TRPV4 receptors in human 
bladder mucosa. The data show species similarity to GP and 
support functional importance of this receptor in maintaining 
basic physiological function of the bladder across the species 
(Figure 6C).
TRPV4 activity in pathological bladders
The ability of the urothelial tissue to release ATP was as-
sessed in human OAB bladder mucosa. Bladder mucosal 
biopsies from six patients with OAB were examined. 
Spontaneous basal release of ATP from bladder mucosa was 
increased in OAB bladders compared to that in non-OAB 
bladders (ρmolar ATP release: OAB, 250 [70, 575]; control: 
23 [19, 64], P < .05, Figure 12B). GSK enhanced ATP re-
lease from basal levels in all OAB samples. The relative in-
crease in ATP release from basal levels was similar in both 
OAB samples and non-OAB controls (OAB: 263 ± 46% of 
basal level vs. control: 258 ± 72% (n = 14); P > .05), sug-
gesting that the proportionate drug effect of GSK on ATP 
release is similar in both groups. However, importantly, the 
quantity of ATP released by TRPV4 agonist in OAB samples 
was greater than that in control bladders; the peak ATP level 
and the net increase in ATP release were much higher from 
the overactive bladders (peak ATP levels, ρmoles/g tissue/
min; OAB, 693 ± 239 (n = 6) vs. control, 190 ± 98 (n = 14), 
P < .05; net increase: OAB, 190 ± 98 (n = 6) vs. control, 
88 ± 49 (n = 14), P < .05, Figure 12C). The proportional 
increase in ATP release triggered by GSK was not correlated 
with age in the non-OAB control group (Figure 12D(ii)). 
However, this increase was positively correlated with age in 
the OAB group (Figure D(i)) These data suggest that urothe-
lial tissue in human OAB bladders spontaneously releases 
more ATP than that in control bladders and greater quantity 
of ATP is released from the OAB urothelium by TRPV4 ac-
tivation. Importantly, the fractional increase in ATP release 
from OAB samples in response to GSK is closely correlated 
to age, suggesting a specific role of aging in regulation ATP 
release in OAB development.
F I G U R E  1 1  Effect of aging on TRPV4 expression and 
function in GP bladder tissue. A, Representative blot of TRPV4 
(98 kDa, probed using Abcam primary Ab) and β-actin loading control 
(42 kDa; RBL: rat brain lysate Muc: mucosa, SM: smooth muscle). 
B, Quantified data of TRPV4 expression by densitometry. Each 
TRPV4 band is normalized to corresponding loading control. Samples 
duplicated and averaged. Aging tissues have significantly higher 
TRPV4 expression than young (n = 5). C, GSK significantly enhanced 
ATP release from mucosal strips in both age groups. The quantity 
of basal and GSK-induced ATP release per gram tissue was not 
significantly different between age groups (young GP n = 8, aging GP 
n = 14). Median values [25%, 75%], **P ≤ .01; Wilcoxon for GSK vs 
basal; Mann-Whitney for Aging vs Young
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4 |  DISCUSSION
The data from this study show that TRPV4 receptors are 
differentially expressed throughout the bladder wall with 
predominant expression in the urothelium, and that TRPV4 
receptors regulate key physiological endpoints in both the 
urothelium and bladder smooth muscle, emphasizing the 
functional importance of this receptor in the bladder. Of sig-
nificance, specific TRPV4 activation evokes significant ATP 
release from native bladder tissue and constitutive TRPV4 
activity leads to ATP release, with the urothelium identi-
fied as the source for such ATP release. A Ca2+- and protein 
tyrosine kinase-dependent signal transduction pathway via 
pannexin channels underlying TRPV4-induced ATP release 
has been elucidated, a novel action of TRPV4 to produce su-
peroxide identified, and pathological significance and human 
relevance demonstrated. To our knowledge, this is the first 
study to use native animal and human bladder tissue to reveal 
F I G U R E  1 2  Effect of TRPV4 activation on human bladder biopsies with or without OAB symptoms. A, GSK (1 μM) significantly enhanced 
ATP release from human mucosal biopsies (non-OAB control). B, Higher spontaneous ATP release from mucosal biopsies in OAB patients (n = 6) 
(vs. non-OAB control, n = 14, P < .05); C, Greater GSK-induced ATP release per unit mass of mucosa in OAB group and net increase in ATP 
release in OAB group compared with controls (P < .05); D correlation between mucosal ATP release and age D(i), Close correlation in OAB 
samples; D(ii), No correlation in control patients. E, Example trace of tension during challenge with 1 μM GSK in human mucosal biopsies: little 
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the mode of action of TRPV4 receptors in native bladder 
tissue, either stretch-independent or stretch-related, and to 
demonstrate pathological and human relevance. These find-
ings suggest species similarity and identify an age-dependent 
change in expression and increased ATP release in overac-
tive bladders. These have important implications in bladder 
pathophysiology.
4.1 | Expression of TRPV4 receptor 
in bladder
Most of early studies on TRPV4 expression by immu-
nostaining or Western blot mainly focused on one tissue 
compartment of the bladder with a single method; thus, rela-
tive tissue distribution has not been determined and cross-
species comparison is unknown.35-37 The current study is a 
conclusive demonstration of the expression and localization 
of TRPV4 throughout guinea-pig and human bladder tis-
sues. In this study, TRPV4 expression was shown by immu-
nostaining and Western blotting in both human mucosa and 
guinea-pig bladder tissues with detailed information on its 
tissue distribution. Confocal immunofluorescence images 
demonstrated TRPV4 expression in the urothelium, subu-
rothelium and detrusor smooth muscle of guinea-pig bladder 
tissue, with highest expression in the urothelium. Western 
blotting results provide further evidence for TRPV4 ex-
pression in both mucosa and detrusor smooth muscle, with 
significantly higher expression in the mucosa. Together, 
these data identify the urothelium as the predominant site 
of TRPV4 expression in the bladder. To our knowledge, this 
is the first study to show expression of TRPV4 in guinea-
pig bladder using these two complementary techniques, and 
to indicate the tissue localization. Importantly, TRPV4 ex-
pression was also demonstrated in human mucosal biopsies 
which corroborates previous preliminary observations.37 
Furthermore, we identified TRPV4 receptors in both guinea-
pig and human suburothelial cells which has not been shown 
before. Because suburothelial cells (interstitial cells/myofi-
broblasts) are in series with urothelial cells to work as a func-
tional syncytium to amplify urothelial signals,10 this finding 
has physiological importance. Of pathological significance, 
we demonstrated an increased TRPV4 expression in both 
mucosa and detrusor smooth muscle from aging bladders. 
This may have implications on TRPV4 function and bladder 
physiology during the aging process.
4.2 | The basic mode of action and 
functional role of TRPV4 receptor in bladder
The role of TRPV4 in normal bladder function has been 
previously investigated by several studies.35,38,51,55 These 
earlier studies have provided important basic biological 
actions of TRPV4 receptors and a physiological role in 
bladder function. In particular, the Nilius group35 has es-
tablished that global TRPV4 knockout mice exhibit re-
duced frequency of voiding contractions in cystometry 
and suppressed spontaneous contractions in bladder strips; 
a decreased intravesical stretch-evoked ATP release was 
found in isolated whole bladders. However, measure-
ment of ATP release directly from isolated urothelium/
mucosa was not performed in this study and tissue-spe-
cific actions remain to be established. Other previous in 
vitro studies focused mainly on cultured urothelial cells 
and used stretch as a method to activate TRPV4 which 
may trigger many other non-specific stretch-sensitive pro-
cesses. However, the mode of action of TRPV4 in native 
urothelial tissue layer, in particular, by specific activa-
tion of this receptor, independent of stretch, has not been 
examined and the mechanisms of action are poorly un-
derstood. To accentuate the physiological relevance, we 
assessed the role of TRPV4 by selective activation of this 
receptor by GSK1016790A without the cofounding influ-
ence of stretch-induced non-specific effects. In the pre-
sent study, we examined the role of TRPV4 on the ability 
of the urothelium to release ATP which acts as a novel 
sensory mediator to activate suburothelial sensory nerves 
and other purinoreceptor expressing interstitial cells and 
the contractility of detrusor smooth muscle which governs 
the voiding function of the bladder. The results provide 
multiple lines of evidence to establish a functional role 
for TRPV4 in urothelial ATP release. Selective activation 
of TRPV4 using GSK1016790A evoked significant and 
reproducible release of ATP from the mucosa of human 
and guinea-pig bladders, demonstrating common func-
tionality of TRPV4 between species. As such, this serves 
as evidence that the TRPV4 activity observed in these ani-
mal models can be translated to humans with confidence. 
Importantly, mucosal strips released far greater quantities 
of ATP per unit of tissue mass than full-thickness strips, 
suggesting the majority of ATP released by the blad-
der in response to TRPV4 activation originates from the 
urothelium. Removal of the mucosa resulted in near com-
plete loss of GSK/TRPV4-induced ATP release, further 
supporting the urothelium as the source of ATP release. 
Furthermore, there is no correlation between the quantity 
of ATP release and magnitude of contraction, implying 
the two phenomena are relatively independent.
Antagonism of TRPV4 with HC-067047 completely 
abolished any GSK-induced ATP release, confirming se-
lectivity of GSK. This is in contrast with previous stud-
ies, where stretch or non-selective 4α-PDD was used for 
TRPV4 activation and the multi-action inhibitor ruthe-
nium red was used as a TRPV4 inhibitor and thus the 
specific properties of TRPV4 could not be determined. 
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Importantly, we show that specific activation of TRPV4 
receptor by agonist without stretch can release significant 
amount of ATP. This implies that activation of the TRPV4 
receptor can occur by chemical signals encountered in 
the tissue environment and in particular under inflamma-
tory conditions with release of endogenous inflammatory 
mediators, even when the bladder is relaxed without any 
mechanical stimulus from bladder distension or contrac-
tile activity. Indeed, burning sensations occur in empty 
bladders during bladder infection and non-infectious in-
flammatory cystitis. This suggests that TRPV4 receptors 
can sense noxious chemical signals and thus serve as a 
sensor of pathology. Furthermore, antagonism with HC-
067047 reduced basal ATP release in the absence of GSK 
in both GP and human mucosa, which has not been re-
ported before. This implies that TRPV4 is active without 
exogenous activators and is therefore activated by endoge-
nous ligands in the tissue that maintains basal ATP release 
by sustaining a “TRPV4 tone.” The native mechano- and 
osmotic environment of bladder tissue may serve as low 
strength mechanical signal. More importantly, the endog-
enous chemical environment may also provide a constant 
chemical stimulus. Changes to these conditions and the 
temperature increase during inflammation may aggravate 
noxious stimuli to up-regulate TRPV4 activity. All these 
emphasize important pathological impact. Currently, ep-
oxyeicosatrienoic acids (EETs) are the only known endog-
enous activators of TRPV4 identified.32,33 TRPV4 channel 
activity can also be enhanced by the Ca2+-CaM complex 
and IP3.56,57 Both spontaneous intracellular Ca2+ release 
and IP3 pathways associated with P2Y receptors exist in 
urothelial cells58 which may enhance TRPV4 activity. Src-
family tyrosine kinases (SFKs) can also sensitize TRPV4 
channel activity and are thought to mediate the channel's 
responses to mechanical/hypotonic stimuli.59,60 SFKs are 
ubiquitously expressed including urothelial cells61 and 
regulate a vast number of cellular processes and responses 
to oxidative stress (reviewed elsewhere62,63) and may be 
available for basal TRPV4 activation, possibly sensitizing 
the receptor for lower level stimulation. How other endog-
enous chemical mediators affect TRP4 activity remains to 
be explored. A role for urothelial TRPV4 in spontaneous 
bladder contractility has been previously demonstrated.35 
Removal of the urothelium and knockout of TRPV4 re-
sulted in reduced spontaneous activity, suggesting that 
urothelial TRPV4 is responsible for this spontaneous ac-
tivity, and not DSM TRPV4. Our identification of signif-
icant ATP release from the native mucosa suggests a role 
for TRPV4 derived basal ATP release from the urothelium 
in driving this TRPV4-dependent spontaneous activity ob-
served previously.
A role for TRPV4 expressed in the DSM has been iden-
tified both here and in previous studies.55,64-66 TRPV4 
activation evoked sustained contractions in intact bladder 
strips of similar magnitude to those evoked by the cholin-
ergic agonist carbachol. These contractions were also ob-
served in denuded DSM strips and therefore suggest that 
direct activation of TRPV4 receptors in the DSM can cause 
DSM contractions, although additional small contrac-
tions could result from an indirect effect of ATP release. 
Consistent with findings from previous studies, this study 
identifies the presence of functional TRPV4 receptors in 
the DSM and further reveals the ability of TRPV4 to di-
rectly contract bladder muscle with a force equaling that of 
muscarinic receptor activation. The magnitude of TRPV4 
activation-induced smooth muscle contraction adds weight 
to its physiological relevance. Thus, these findings reveal 
that TRPV4 activity in DSM may indeed influence blad-
der pathologies associated with muscle over-activity or 
underactivity.67,68
The demonstration of TRRV4-mediated ATP release in 
native bladder tissue suggests that TRPV4 can influence the 
physiology of the bladder. It is currently thought that the 
urothelium senses distension in the bladder during filling 
and communicates this to the underlying tissues by release 
of ATP as a chemical signal. This may be a fundamental pro-
cess in the bladder's overall ability to sense fullness, whereby 
the extent of bladder distension (equating to urine volume) 
is relayed to underlying afferent nerves via an ATP signal 
generated, in part, by TRPV4. ATP acts on P2X3 and P2X2/3 
receptors on suburothelial sensory nerves.3,5,69 These nerves 
continuously convey information regarding urine volume 
to the PMC for voluntary bladder control and perception 
of bladder fullness, initiating urges to void at appropriate 
volumes that induce pressures of 20-25 mm Hg permitting 
correct periodic storage and voiding of urine. Pain is per-
ceived once certain harmful volumes producing pressures of 
30-50 mm Hg are reached.70
4.3 | Stretch and TRPV4 receptors
Mechanical stretch evokes a reproducible ATP release 
from the mucosa. TRPV4 blockade results in a 50% re-
duction of this ATP release. This finding provides new 
evidence for a specific role of TRPV4 in stretch-induced 
ATP release from the native urothelium and its quantita-
tive contribution. This is different from the previous re-
port on cultured urothelial cells where ATP release from 
these cultured cells by stretching the cell adhered to sili-
cone was completely abolished by ruthenium red, implying 
100% contribution of TRPV4 channel to stretch-induced 
ATP release under these conditions.38 This difference can 
be explained by the non-specific inhibitor used previously 
and the different stretch method (silicone gel deformation) 
which is different from mechanical bladder distension. 
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More importantly, the cultured cells may behave differ-
ently from native cells and tissue and the results cannot be 
directly extrapolated to native cells and tissue. It is unlikely 
that all stretch-induced cell responses are solely mediated 
by TRPV4 channels. ENaC channel, gadolinium-sensitive 
stretch-activated channel, and Piezo1 channel have been 
shown to contribute to stretch-induced ATP release in the 
urothelium.9,21,71 Our findings suggest a physiological role 
of TRPV4 channels in regulating urothelial ATP release in 
the normal micturition cycle in response to a physiological 
stimulus—bladder distension/stretch. The mechanisms by 
which stretch activates TRPV4 channels have been studied 
previously in other tissue types and it is currently thought 
that the process requires activation of TRPV4 by EETs, 
generated by PLA2-dependent pathway,32,72 or phospho-
rylation by SFKs,59,60 or indeed both. However, the pos-
sibility of direct activation by mechanical force has not 
been excluded73 and therefore further research is required 
to fully establish the mechanisms underlying stretch ac-
tivation of TRPV4. The downstream mechanisms under-
lying TRPV4-induced ATP release are elucidated in the 
present study. We show that protein tyrosine kinase activ-
ity is required for GSK-induced ATP release. This was not 
observed in a previous study on cultured cells using the 
TRPV4 agonist 4α-Phorbol 12-13-dicaprinate (4αPDD), 
however that was likely due to different activation mecha-
nisms.74 Furthermore, the signaling pathways in cultured 
cells may be different from those in native cells emphasiz-
ing the need to examine these mechanisms in native tissue.
4.4 | Mechanisms of action
This study found that GSK/TRPV4-induced ATP release 
is mediated mainly by conductive pathways (connexin and 
pannexin channels; 90%), with little or no contribution 
from vesicular transport. Pennexin-conductive fluxes have 
been shown to contribute to intrinsic ATP release from the 
urothelium by our earlier study.24 The current study shows 
that this pathway is mainly involved in TRPV4-mediated 
ATP release. The process was also tightly dependent on ex-
tracellular Ca2+ entry, the main action mediated by TRPV4 
channels. This was further evidenced by live-cell calcium 
imaging, which identified a rise in [Ca2+]i upon TRPV4 
activation in freshly isolated GP urothelial cells. The far 
greater response of Ca2+ rise by TRPV4 activation than 
that by activation of the main functional receptor-puriner-
gic receptor in the urothelium by ATP shows crucial role 
of TRPV4 receptors in urothelial function and intracellular 
Ca2+ rise as the key second messenger in TRPV4 signaling. 
Blockers of Ca2+-activated chloride channels had no effect 
on GSK-induced ATP release, excluding them from the 
mechanism. However, inhibition of protein tyrosine kinase 
significantly suppressed ATP release, suggesting that pro-
tein tyrosine kinase, which is associated with cytoskeleton 
restructuring and focal adhesion proteins,75 and other ki-
nase-dependent cellular pathways is one of the downstream 
mechanisms. Previous studies on cultured cells showed that 
stretch or the non-specific activator 4aPDD could release 
ATP or induce a Ca2+ rise, suggesting the potential role 
of Ca2+ rise in ATP release; however, the causal relation-
ship was not established, and the upstream and downstream 
coupling molecules were not examined. The collective 
findings from the present study suggest a mechanism 
whereby stretch or non-stretch chemical activators activate 
TRPV4 receptors via SFK-mediated phosphorylation of 
the channel; TRPV4 mediates Ca2+ influx raising [Ca2+]i; 
which activates a Ca2+-dependent, hemichannel-mediated 
ATP release mechanism, likely through pannexin-1 chan-
nels76 and with intracellular tyrosine kinase as downstream 
pathway.
The study also discovered a long-open state of the TRPV4 
channels as evidenced by a prolonged intracellular Ca2+ rise 
in urothelial cells and sustained contractions in smooth mus-
cle not observed with purinergic or muscarinic activation. 
This suggests that TRPV4 receptors can maintain activity in 
response to constant low levels of noxious stimuli during in-
flammation and ischemic conditions such as outflow obstruc-
tion and bladder hypertrophy. This is consistent with basal 
activity as demonstrated by the action of the TRPV4 antag-
onist in the absence of exogenous stimuli and has important 
pathological implications.
A fundamental role for TRPV4 in urothelial trans-
duction of sensory information regarding bladder disten-
sion has been identified by this investigation, which may 
also have implications in bladder overactivity and pain. 
Urothelial TRPV4 may not only mediate volume-depen-
dent pain perception in the bladder under physiological 
conditions but may also induce pain and respond to inflam-
matory stimuli as a result of various pathologies includ-
ing bladder inflammation. Changes in the expression and 
function of TRPV4 that result from aging or pathology that 
have indeed been identified, may influence painful bladder. 
TRPV4-mediated nociception in the rat has been shown to 
be enhanced by PGE2, a hyperalgesic inflammatory medi-
ator.74 As such, inflamed bladders could enhance TRPV4 
mediated nociception in the same manner, implicating 
TRPV4 in painful bladder pathologies.
4.5 | ROS production: a novel mode of 
action for TRPV4
The current study identified a further, potentially pathologic 
output of TRPV4, where TRPV4 activation appears to increase 
bladder superoxide (O2−) production. O2− plays physiological 
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roles in cellular signaling, for example in cell growth, where 
low levels stimulate cell proliferation77 and excessive O2− 
contributes to oxidative damage and many pathological con-
ditions. TRPV4 activation can initiate mitochondrial ROS 
production in human coronary artery strips for vasodilation.78 
Our novel findings suggest that TRPV4 activation, possibly 
by stretch, induces NADPH-dependent ROS production for 
ROS-mediated physiological processes in the urothelium. 
More importantly, TRPV4-mediated ROS production may 
contribute to oxidative stress and bladder pathologies.
A previous study shows that intravesical administration 
of hydrogen peroxide induces overactivity of the blad-
der.79,80 Substance P has been reported to cause bladder 
smooth muscle contractions and also induce ROS produc-
tion.79,80 In addition, ROS significantly up-regulates the 
phosphorylation of TRPV4 by SFKs,60 presenting a pos-
itive feedback on TRPV4, where TRPV4-mediated ROS 
production enhances receptor activity. As ROS overproduc-
tion is an important pathological process in inflammation, 
many chronic diseases and aging; the ability of TRPV4 to 
stimulate ROS production in bladder tissue identifies a new 
pathway whereby these channels mediate aging, painful 
bladder, and overactivity.
4.6 | Human relevance and pathological 
significance
The function of TRPV4 in human urothelium has not been 
experimentally examined previously. An early meeting 
abstract reported increased bladder contractions in mouse 
and rat by a non-specific TRPV4 activator and proposed an 
interesting idea that TRPV4 contributes to bladder overac-
tivity.81 However, this was a simple contraction of normal 
bladder tissue and bladder overactivity was not substan-
tiated, and no human tissue or pathological overactive 
bladder was examined. Our study provides evidence that 
TRPV4 receptors are expressed in native human bladder 
mucosa with the highest density in the urothelial cells con-
firming a previous report39 and provides the first evidence 
that these receptors function by augmenting urothelial ATP 
release—a key urothelial function. Thus, TRPV4 channels 
are important functional regulators in human bladder with 
specific action on urothelial function with both sensory and 
motor activities. The attenuation of spontaneous release of 
ATP from the human mucosa by a TRPV4 antagonist in the 
absence of any exogenous activators further demonstrates 
intrinsic TRPV4 activity in human bladder tissue and the 
wide functional implications of this receptor in maintaining 
resting activity of the urothelium and hence normal blad-
der physiology. The consistent physiological responses and 
mode of action between human and guinea-pig preparations 
provide evidence that TRPV4 receptors in the bladder are 
universal functional regulators across animals and humans. 
This specifically identifies a role for TRPV4 in chemi-
cally induced and stretch-evoked urothelial ATP release in 
physiologically relevant bladder strips and reveals age-de-
pendent changes that may influence OAB, highlighting the 
multifactorial potential of TRPV4 to contribute to OAB. 
Importantly, reduced basal ATP release was achieved with 
selective blockade of TRPV4, further indicating the poten-
tial of this receptor as a drug target.
Importantly, this study provides the first experimental ev-
idence that TRPV4 receptors contribute to greater ATP re-
lease in pathological human OAB bladders. This highlights 
the role of this channel in augmentation of ATP release and 
the associated downstream sensory and motor up-regulation 
in the pathogenesis of bladder overactivity. Furthermore, the 
data also show for the first time that ageing facilitates TRPV4 
activation in OAB urothelium as evidenced by increased pro-
portional ATP release in response to TRPV4 activator. This 
mode of action is characteristic of pathological OAB blad-
ders but not in non-OAB bladders where no correlation can 
be seen, thus uncovering a pathology-specific mechanism in 
a human condition.
4.7 | Summary
In summary, this is the first study to demonstrate a funda-
mental physiological role of TRPV4 in regulating urothelial 
ATP release and bladder function across species with human 
relevance and identifies the mode of action and mecha-
nisms in stretch-independent responses. Of pathological 
significance, this study also provides the first evidence for 
TRPV4 involvement in aging, oxidative stress, and overac-
tive bladders.
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